trending Market Intelligence /marketintelligence/en/news-insights/trending/RM-xYhNgYULgk-QdVdhf5A2 content esgSubNav
In This List

Bristol-Myers' Opdivo gets US FDA approval for colorectal cancer

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Bristol-Myers' Opdivo gets US FDA approval for colorectal cancer

The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co.'s Opdivo in another cancer indication.

The therapy can now be used to fight a certain type of metastatic colorectal cancer that progressed after receiving fluoropyrimidine, oxaliplatin and irinotecan.

The indication was approved under accelerated approval supported by overall response rate and duration of response in a phase 2 trial.

Opdivo is approved for a number of cancers, including lung cancer.